AAV2-GDNF gene therapy
DrugBilateral image-guided infusion of AAV2-GDNF into putamen, single dose
Other names: Biological
NCT Number: NCT06285643
The objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.
Interested in participating?
Request Info45 year–75 year
All sexes
Interventional
Phase 2
Charité - Universitätsmedizin Berlin (Surgical), Berlin, Germany
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Age
Exclusion criteria
Bilateral image-guided infusion of AAV2-GDNF into putamen, single dose
Other names: Biological
Bilateral partial burr/twist holes without dural penetration
Time frame: 18 months
Normalized Good ON time per Hauser Diary
Contact information is provided by the study sponsor or research team.
Gayathri Palety, MD
CONTACT
Nisha Chhabria, MD
CONTACT
AskBio Inc
Industry
A Phase 2, Randomized, Double-blind, Sham Surgery-controlled Study of the Efficacy and Safety of Intraputaminal AAV2-GDNF in the Treatment of Adults With Moderate Stage Parkinson's Disease
Acronym: REGENERATE-PD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06570824
Basal Ganglia Diseases, Brain Diseases
Hvidovre, Denmark
View Trial DetailsNCT06993142
Basal Ganglia Diseases, Behavior
Rochester, New York, United States
View Trial DetailsNCT06193252
Basal Ganglia Diseases, Behavior
Nijmegen, Gelderland, Netherlands
View Trial DetailsNCT07399496
Basal Ganglia Diseases, Brain Diseases
Charleston, South Carolina, United States
View Trial Details